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Uterine leiomyomas have been reported to metastasize to various organs including the lungs, skeletal muscles, bone marrow,
peritoneum, and heart. They may present with symptoms related to the metastases several years after hysterectomy. These tumors
regress after menopause, and it is rare to detect active tumors in postmenopausal women. Despite their ability to metastasize, they
are considered to be benign due to the lack of anaplasia. Pulmonary benignmetastasizing leiomyoma is usually detected in the form
of pulmonary nodules incidentally on imaging. Tissue biopsy of these nodules is required to identify them as benign metastasizing
leiomyomas. Immunohistochemical analysis and molecular profiling may further help detect any malignant transformation in
it. Untreated pulmonary benign metastasizing leiomyoma may result in the formation of cystic structures, destruction of lung
parenchyma, and hemothorax andmay cause respiratory failure. Surgical resection and hormonal therapy help prevent progression
of this disease and provide an avenue for a cure.
1. Introduction
Uterine leiomyomas are benign tumors which affect up
to 80% of females in their lifetime [1]. Family history,
nulliparity, obesity, and race have been established as risk
factors for development of uterine leiomyoma [2, 3]. They
are more prevalent in women of African descent and cause
infertility in up to 3% of patients [4, 5]. Metastasis of
uterine leiomyoma was first described by Steiner in 1939
[6]. Uterine leiomyomas are considered to be benign but
have been reported to metastasize to various organ including
the lymph nodes, bones, skeletal muscles, bone marrow,
nerves, peritoneum, retroperitoneum, heart, mediastinum,
and lungs [7–13]. Histologically, they consist of dense nodules
with cells and extracellular material arranged in a trabec-
ular pattern punctuated by foci of cystic degeneration and
microcalcifications. Microscopically, the trabecular pattern
consists of spindle-shaped smooth muscle cells with abun-
dant eosinophilic cytoplasm and elongated nuclei. How-
ever, several subtypes exist: benign metastasizing leiomyoma
(BML) which is most often detected in lungs as nodules and
consists of densely packed smooth muscle cells; epithelioid
leiomyoma, consisting of polygonal cells; cellular leiomyoma,
consisting of smooth muscles and collagen; vascular leiomy-
oma, consisting of abundant blood vessels; leiomyoma with
tubules which consists of tubular structures; lipoleiomyoma,
consisting of smooth muscle cells and adipocytes; myxoid
leiomyoma, consisting of smooth muscles interspersed in
myxoid substance; atypical leiomyoma, consisting of atypical
cells distributed in extracellular matrix [14].
Metastatic foci of leiomyoma have been discovered up
to 24 years after hysterectomy for benign leiomyoma of the
uterus and the average age of presentation is 48 years [15, 16].
BML has been postulated to be a result of hematogenous
spread from a benign uterine leiomyoma. It is currently
unclear if hematogenous spread is an endogenous process
characteristic of the primary disease or if it is facilitated
by procedures such as dilatation and curettage. BML is
considered benign despite its ability to metastasize because
of the lack of mitotic figures and anaplasia. Pulmonary
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Figure 1: (a) CXR taken two years before presentation. (b) CXR at the time of presentation shows a white-out of the right hemithorax.
BML is often seen in premenopausal women but is rarely
seen in postmenopausal women. This case report describes
the clinical presentation, pathological features, and clinical
course of a patient who was diagnosed with pulmonary BML
after she was found to have a hemothorax.
2. Case Summary
The patient is a 64-year-old lady with a past medical his-
tory significant for hypertension, hyperlipidemia, hypothy-
roidism, and diabetes who presentedwith rapidly progressing
dyspnea on exertion for the past two weeks. This was
accompanied by a new onset progressive orthopnea and
right-sided back pain of the sameduration. She denied cough,
hemoptysis, fever/chills, chest pain, and leg swelling. She had
seen her primary care physician recently and was prescribed
a trial of albuterol and was scheduled for an echocardiogram.
Notably, her primary care physician documented clear lungs
bilaterally, and the patient reported no improvement in her
dyspnea with albuterol. She denied recent travel and had no
history of a positive purified protein derivative (PPD) test.
Two years ago, she was noted to have increased abdominal
girth, and imaging showed uterine and ovarian masses.
She subsequently underwent total abdominal hysterectomy
with bilateral salpingo-oophorectomy, and pathology showed
benign leiomyomas. During the same time, she was also
diagnosed with multiple lung nodules and underwent a
CT-guided biopsy which showed atypical cells and smooth
muscle andwas inconclusive. In the same year, she underwent
colonoscopy which showed a benign polyp and a mammo-
gram which showed dense irregular tissue in her right breast.
Due to the discomfort experienced due to the CT-guided
biopsy, she refused to have repeat evaluation of her lung
nodules and was lost to follow-up. Her family history was
significant for colon cancer in her mother. She worked in
the office of a pediatrician and was an active smoker but
denied consumption of alcohol or usage of intravenous drugs.
Her medications included lisinopril, hydrochlorothiazide,
levothyroxine, and an albuterol inhaler.
During her current presentation, her physical examina-
tion was remarkable for oxygen saturation of 98% on 2 L
of nasal cannula, absence of jugular venous distension and
any lymphadenopathy, the presence of a 2 × 3 cm irregular
and mobile mass in her right breast, clear breath sounds
in the left lung but audible breath sounds only in the apex
of the right lung, and dullness to percussion up to two-
thirds of the right lung field. The abdomen was benign,
and there was no evidence of pedal edema. Her labs were
significant for leukocytosis (15.7 k/mm3), thrombocythemia
(437 k/mm3), andmild hyponatremia (133mEq/L). Her chest
X-ray (CXR) revealed a complete white-out of the right side
when compared to her previous CXR (Figures 1(a) and 1(b)).
A bedside ultrasound showed a complex hypoechoic space
with no clear pocket for thoracentesis. A chest CT with
contrast showed the entire right hemithorax filled with fluid
and an irregular mass (Figures 2(b) and 2(c)). Placement
of a pigtail catheter resulted in drainage of 1500 cc of
sanguinous fluid with RBC of 1.5 million/mm3, glucose of
28, LDH of 966 IU/mL, and a total protein of 5.6 g/dL. The
fluid cytology showed blood and inflammatory cells, but no
malignant cells were detected. Flow cytometry did not reveal
cells with markers characteristic of lymphoma. During the
next 24 hours, the chest tube drained 2000 cc of sanguinous
fluid, and her hemoglobin dropped from 12.4 to 11 g/dL. The
patient reported a significant improvement in her symptoms.
However, a repeat CXR showed a significant amount of fluid
in the lower lung field of the right lung. A repeat chest CT
was suspicious of a bleeding vessel from a necrotic mass
in the right middle lobe (Figures 3(a), 3(b), and 3(c)). She
was taken to the OR and underwent a right-sided video-
assisted thoracoscopic surgery (VATS) which was converted
to right-sided open thoracotomy. During the procedure,
approximately 2500 cc of sanguinous fluid was removed from
the hemithorax, and the right middle lobe was removed after
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Figure 2: (a) Transverse section of thorax by CT before presentation. (b) Transverse section of thorax by CT at presentation showing fluid-
filled right hemithorax with an irregular mass. (c) Coronal section of thorax by CT at presentation showing fluid-filled right hemithorax with
an irregular mass.
(a) (b) (c)
Figure 3: (a) CXR showing residual lower lobe collection of fluid after insertion of chest tube. (b) Transverse section of thorax by CT showing
restoration of lung parenchyma in the upper lobe of the right lung. (c) Coronal section of thorax by CT showing a significant collection of
fluid in the middle and lower right lobes of the lung.
a large bleeding mass was noted in it. The intraoperative
frozen section pathology revealed a spindle cell mass. After
partial decortication, the remaining parts of the right lung
was successfully reinflated. The pathological examination of
the excised lung mass revealed two foci of metastasizing cel-
lular leiomyoma with minimal cellular atypia and occasional
mitoses. No necrosis or lymphovascular invasion was noted,
and the bronchial and vascular margins were negative. The
foci showed spindle cells and stained positive for smooth
muscle actin (SMA), vimentin, desmin cytokeratin 7 (CK 7)
(Figures 4(a)–4(f)). The pulmonary lesions were found to be
histologically similar to uterine leiomyoma and did not meet
the histological criteria for sarcoma. Follow-up CXRs taken
on postoperative days 1 and 16 showed gradual but complete
resolution of the right-sided mass (Figures 5(a) and 5(b)).
3. Discussion
BML has been observed to express estrogen and proges-
terone receptors and is known to regress during pregnancy,
after menopause and with selective estrogen modulator
therapy [17]. This may explain the relative paucity of medical
literature on BML in postmenopausal women. Lungs are the
most common site of metastasis for BML, but pulmonary
BML in postmenopausal women has been described only
in a handful of cases [18–22]. A majority of premenopausal
women with pulmonary BML have multiple lung nodules,
and a minority of patients have solitary lung nodules [23].
The monoclonal origin of BML has been established by cyto-
genetic studies [24]. It has been postulated that pulmonary
BML may specifically arise from distinct subset of cells
in the uterine leiomyoma with characteristic chromosomal
aberrations of 19q and 22q deletions [25]. Most patients with
pulmonary BML are asymptomatic and are diagnosed when
pulmonary lesions are incidentally found on imaging. It is
rarely associated with another malignancy, but association
with primary lung cancer has been documented [26]. In the
absence of tissue diagnosis, these lesions may be differenti-
ated from primary lung cancer due to their low FDG activity
onPET scans [27].However, in the presence of a known tissue
diagnosis of pulmonary benign leiomyoma, if some FDGavid
lesions are noted amongst other non-FDG lesions on PET,
leiomyosarcoma should be suspected [28, 29]. Detection of
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Figure 4: (a) Hematoxylin and Eosin (H&E) stain at low magnification showing two foci of BML. (b) H&E stain at a higher magnification
showing trabeculated arrangement of spindle cells. (c), (d), (e), and (f) Immunohistochemical staining positive for SMA, vimentin, desmin,
and CK 7.
microRNA 221 (miR-221) has been recently shown to help
differentiate leiomyoma from leiomyosarcoma [30].
Management of pulmonary BML depends on the extent
of disease, presence of estrogen and progesterone receptors
on the tumor, and the age of the patient. Preoperative treat-
ment with GnRH agonists has been utilized to reduce tumor
size and bleeding in women with uterine leiomyoma, but its
role in treating pulmonary BML in postmenopausal women
has not been clearly established. Most post-menopausal
women with limited disease and with positive expression of
estrogen receptors respond favorably to hormonal therapy
with selective estrogen receptor modulator and aromatase
inhibitors [31]. A combination of GnRH agonists and aro-
matase inhibitors has been shown to be effective in reducing
tumor burden in patients with metastatic leiomyoma [32].
However, surgical resection may become necessary if the
tumor results in complications such as the development of a
hemothorax. Notably, patients with pulmonary lesions which
are not resected and are not treated with hormonal therapy
may develop cysts in the lung which may destroy the entire
lung cavity [33]. Pulmonary embolism has been reported to
be associated with pulmonary BML, and anticoagulationmay
be reasonable, especially in patients with heavy tumor burden
[34].
Hemothorax is a rare manifestation of pulmonary BML.
There has been one report of pulmonary BMLnoted in a nod-
ule in the pulmonary artery which was successfully resected
[35]. Pleural collection of blood due to pulmonary BML may
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Figure 5: (a) CXR taken on postoperative day 1 which shows significant resolution of the fluid collection from the right hemithorax; (b) CXR
taken on post-operative day 16 which shows complete resolution of the fluid collection from the right hemithorax.
also get superinfected and present as empyema [36].This case
illustrates the need to consider pulmonary BML as a possible
etiology of hemothorax in post-menopausal women.
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